Sysmex Corp (6869) - Part 2

Valuable growth options in Alzheimer's diagnosis and surgical robots

We’ll dive deep into Sysmex’s two growth options: Alzheimer’s diagnosis and surgical robots. Bear in mind that these are not the only growth options that Sysmex has. For example, the company has early stage businesses in the fields of genomics and regenerative medicine as well. However, I have chosen to zoom in on the two in particular, as I believe investors can build a certain degree of conviction around them based on the following:

• They have passed an important point in terms of commercial milestone, which I define as having a fully developed, revenue-generating product which has already obtained approval from at least one major regulatory body.

• Sysmex has the right to win in these areas - it’s positioned advantageously to possibly lead or capture a meaningful part of the market - either globally (Alzheimer’s) or in an important local market (surgical robots).

• Finally, the businesses have the potential to become financially material, looking out five years ahead.

I believe these are “options with conviction”, if I’m allowed to make up that phrase.

So let’s dive in.